Five Prime Therapeutics, Inc.
(NASDAQ : FPRX)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Interested in Gold Updates?
Receive the latest updates on the gold and silver markets.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
MRNAModerna, Inc. -3.01%152.520.0%$4782.73m
NVAXNovavax, Inc. -2.25%126.2592.9%$675.98m
BNTXBioNTech SE 1.11%120.000.0%$672.24m
AMGNAmgen, Inc. 1.01%229.211.3%$578.56m
GILDGilead Sciences, Inc. 1.15%61.561.0%$506.97m
BIIBBiogen, Inc. 0.73%245.871.7%$496.02m
REGNRegeneron Pharmaceuticals, Inc. -1.28%492.452.7%$472.10m
VRTXVertex Pharmaceuticals, Inc. 0.64%228.321.9%$455.95m
ILMNIllumina, Inc. 1.35%350.663.5%$426.07m
EXASEXACT Sciences Corp. 1.68%132.8719.6%$207.83m
SGENSeagen Inc. -0.52%179.235.8%$156.07m
BGNEBeiGene Ltd. 0.71%222.881.4%$141.27m
CRSPCRISPR Therapeutics AG 5.04%147.540.6%$137.84m
TXG10X Genomics, Inc. 2.63%149.040.0%$136.40m
SRNESorrento Therapeutics, Inc. 0.00%7.971.4%$136.15m

Company Profile

Five Prime Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on discovering and developing novel protein therapeutics. Its product candidates includes, Cabiralizumab(FPA008), Bemarituzumab(FPA144), and FPA150. The FPA008 is an antibody that inhibits colony stimulating factor-1, or CSF1, receptor, or CSF1R, that are developing in rheumatoid arthritis and plan to clinically develop in pigmented villonodular synovitis, or PVNS, and in combination with nivolumab in multiple cancers. The FPA144 is an antibody that inhibits fibroblast growth factor receptor 2b, or FGFR2b, that are developing to treat patients with gastric cancer. The FPA150 is a CD8 T cell checkpoint which targets B7-H4 that is developing as a monotherapy in multiple cancers. The company was founded by Lewis T. Williams in December 2001 and is headquartered in South San Francisco, CA.